Lin BioScience Company Description

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases.

Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes.

The company is headquartered in Taipei, Taiwan.

Lin BioScience, Inc.

Country	Taiwan
Industry	Biotechnology
Sector	Healthcare
CEO	Zhengqi Wang

Contact Details

Address: No. 68, Zhongxiao East Road Taipei, 110 Taiwan
Phone	886 2 8780 5008
Website	linbioscience.com

Stock Details

Ticker Symbol	6696
Exchange	Taipei Exchange
Fiscal Year	January - December
Reporting Currency	TWD
ISIN Number	TW0006696008
SIC Code	2836

Key Executives

Name	Position
Dr. Zhengqi Wang M.B.A., Ph.D.	President and CSO
Serena Chen	Chief Financial Officer
Hongwei Chen	Chief Operating Officer